Our top pick for
Centene Corporation is a healthcare plans business based in the US. Centene Corporation shares (CNC) are listed on the NYSE and all prices are listed in US Dollars. Centene Corporation employs 71,300 staff and has a trailing 12-month revenue of around USD$104.2 billion.
|52-week range||USD$43.96 - USD$74.7|
|50-day moving average||USD$61.7742|
|200-day moving average||USD$62.0673|
|Wall St. target price||USD$80.74|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$3.12|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Centene Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Centene Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Centene Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Centene Corporation shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Centene Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8086. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Centene Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Centene Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$5.4 billion.
The EBITDA is a measure of a Centene Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$104.2 billion|
|Operating margin TTM||3.95%|
|Gross profit TTM||USD$18 billion|
|Return on assets TTM||4.68%|
|Return on equity TTM||9.28%|
|Market capitalisation||USD$34.5 billion|
TTM: trailing 12 months
There are currently 8.5 million Centene Corporation shares held short by investors – that's known as Centene Corporation's "short interest". This figure is 0.6% down from 8.5 million last month.
There are a few different ways that this level of interest in shorting Centene Corporation shares can be evaluated.
Centene Corporation's "short interest ratio" (SIR) is the quantity of Centene Corporation shares currently shorted divided by the average quantity of Centene Corporation shares traded daily (recently around 3.8 million). Centene Corporation's SIR currently stands at 2.21. In other words for every 100,000 Centene Corporation shares traded daily on the market, roughly 2210 shares are currently held short.
However Centene Corporation's short interest can also be evaluated against the total number of Centene Corporation shares, or, against the total number of tradable Centene Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Centene Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Centene Corporation shares in existence, roughly 10 shares are currently held short) or 0.0166% of the tradable shares (for every 100,000 tradable Centene Corporation shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Centene Corporation.
Find out more about how you can short Centene Corporation stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Centene Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.72
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Centene Corporation's overall score of 28.72 (as at 01/01/2019) is pretty good – landing it in it in the 36th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Centene Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 5.14/100
Centene Corporation's environmental score of 5.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Centene Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 21.92/100
Centene Corporation's social score of 21.92 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Centene Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 10.66/100
Centene Corporation's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Centene Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Centene Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Centene Corporation has, for the most part, managed to keep its nose clean.
|Total ESG score||28.72|
|Total ESG percentile||36.42|
|Environmental score percentile||7|
|Social score percentile||7|
|Governance score percentile||7|
|Level of controversy||2|
We're not expecting Centene Corporation to pay a dividend over the next 12 months.
Centene Corporation's shares were split on a 2:1 basis on 7 February 2019. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Centene Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Centene Corporation shares which in turn could have impacted Centene Corporation's share price.
Over the last 12 months, Centene Corporation's shares have ranged in value from as little as $43.96 up to $74.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Centene Corporation's is 0.5144. This would suggest that Centene Corporation's shares are less volatile than average (for this exchange).
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; health, triage, wellness, and disease management services; and vision and dental, and management services, as well as care management software that automate the clinical, administrative, and technical components of care management programs; staffing services; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.